Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current antiarrhythmic therapy overview.

A J Camm1

  • 1St. George's Hospital Medical School, University of London, England.

Cardiovascular Drugs and Therapy
|June 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adverse effects of amiodarone at low dose: plus ça change.

Journal of the American College of Cardiology·1997
Same author

Atrial premature beats preceding episodes of paroxysmal atrial fibrillation: factorial analysis of a prediction system.

Pacing and clinical electrophysiology : PACE·1997
Same author

Exercise-induced T-wave alternans as a marker of high risk in patients with hypertrophic cardiomyopathy.

Japanese circulation journal·1997
Same author

Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction.

Circulation·1997
Same author

Chlamydia pneumoniae and coronary heart disease.

BMJ (Clinical research ed.)·1997
Same author

Amiodarone after myocardial infarction: EMIAT and CAMIAT trials.

Lancet (London, England)·1997
Same journal

Methodological Considerations in Evaluating Plaque Stabilization in Patients with High Lipoprotein(a).

Cardiovascular drugs and therapy·2026
Same journal

Association of In-Hospital Dapagliflozin Initiation with Favorable left Ventricular Remodeling in Patients with Acute Myocardial Infarction and Heart Failure: A Retrospective Cohort Study.

Cardiovascular drugs and therapy·2026
Same journal

Impact of Nitric Oxide Metabolites On Early Perioperative Biochemical Changes and Postoperative Complications in High-BMI Patients Undergoing On-Pump CABG: an Exploratory Observational Cohort Study.

Cardiovascular drugs and therapy·2026
Same journal

Comparative Cardiovascular, Lipid, and Safety Effects of Lipid-Modifying Therapies in Diabetes: An Agent-, Class-, and Dose-Level Network Meta-Analysis.

Cardiovascular drugs and therapy·2026
Same journal

Cardiovascular Genetic Epidemiology in the Genome-Wide Era: From Association Discovery to Mechanistic Dissection and Clinical Translation.

Cardiovascular drugs and therapy·2026
Same journal

Shenfu Injection Inhibits Cardiac Fibroblast Activation and Improves Myocardial Fibrosis by Down-regulating M1 Macrophage-Derived Exosomal miR-155-5p.

Cardiovascular drugs and therapy·2026
See all related articles

Cardiac arrhythmias, ranging from mild to life-threatening, are common. Management options include reassurance, physical maneuvers, drugs, devices, and ablation, tailored to arrhythmia type and patient health.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Internal Medicine

Background:

  • Cardiac arrhythmias are prevalent health issues in Western populations.
  • Arrhythmias present a spectrum of severity, from benign to life-threatening conditions.

Purpose of the Study:

  • To outline the diverse management strategies for cardiac arrhythmias.
  • To emphasize the individualized approach to arrhythmia treatment based on specific patient factors.

Main Methods:

  • Review of established treatment modalities for cardiac arrhythmias.
  • Analysis of factors influencing clinical decision-making in arrhythmia management.

Main Results:

  • Five primary management categories exist: reassurance, physical maneuvers, antiarrhythmic drugs, implantable electronic devices, and ablation.

Related Experiment Videos

  • Treatment aims to terminate, prevent recurrence, or control the rate of arrhythmias.
  • Cure may be possible by addressing the anatomical substrate.

    • Conclusions:

    • The selection of arrhythmia management depends critically on the arrhythmia's characteristics and the patient's overall health status.
    • A personalized treatment strategy is essential for effective cardiac arrhythmia care.